Synergy Pharmaceuticals Inc. (SGYP)

1.85
0.02 1.10
NASDAQ : Health Technology
Prev Close 1.87
Open 1.88
Day Low/High 1.84 / 1.92
52 Wk Low/High 1.68 / 5.97
Volume 3.72M
Avg Volume 6.37M
Exchange NASDAQ
Shares Outstanding 246.66M
Market Cap 500.72M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc. (SGYP)

The Klein Law Firm Reminds Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc. (SGYP)

The Klein Law Firm announces the commencement of an investigation of Synergy Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Lawsuit Filed Against Synergy Pharmaceuticals Inc.

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a shareholder class action lawsuit has been filed against Synergy Pharmaceuticals Inc.

SYNERGY PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Synergy Pharmaceuticals, Inc. To Contact The Firm

SYNERGY PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Synergy Pharmaceuticals, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Synergy Pharmaceuticals, Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc.

The Klein Law Firm Notifies Investors Of An Investigation Concerning Possible Violations Of Federal Securities Laws By Synergy Pharmaceuticals Inc.

The Klein Law Firm announces the commencement of an investigation of Synergy Pharmaceuticals Inc.

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

SGYP INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Synergy Pharmaceuticals Inc.

SGYP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

SGYP SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Notifies Investors Of An Investigation Involving Possible Securities Fraud Violations By The Board Of Directors Of Synergy Pharmaceuticals Inc.

The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Synergy Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that the Compensation Committee of the Board...

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. - SGYP

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc. - SGYP

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Achieves Cash Balance Requirement To Access Additional Capital

Synergy Pharmaceuticals Achieves Cash Balance Requirement To Access Additional Capital

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has met the cash balance...

Interesting SGYP Put And Call Options For March 16th

Investors in Synergy Pharmaceuticals Inc saw new options begin trading this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new March 16th contracts and identified one put and one call contract of particular interest.

The January Effect Is on Time This Year

The January Effect Is on Time This Year

I continue to believe that biotech and biopharma stocks will outperform in 2018.

Interesting SGYP Put And Call Options For February 2018

Investors in Synergy Pharmaceuticals Inc saw new options become available this week, for the February 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SGYP options chain for the new February 2018 contracts and identified one put and one call contract of particular interest.

Gary S. Jacob, Ph.D., Executive Chairman, Synergy Pharmaceuticals Inc. (Photo: Business Wire)

Gary S. Jacob, Ph.D., Executive Chairman, Synergy Pharmaceuticals Inc. (Photo: Business Wire)

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Troy Hamilton, Pharm.

First Week of SGYP July 2018 Options Trading

Investors in Synergy Pharmaceuticals Inc saw new options begin trading this week, for the July 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Synergy Pharmaceuticals Announces Pricing Of Offering Of Common Stock And Warrants

Synergy Pharmaceuticals Announces Pricing Of Offering Of Common Stock And Warrants

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, today announced the pricing of its underwritten offering of...

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

5 Small Biotechs Receive Shots in the Arm

5 Small Biotechs Receive Shots in the Arm

Favorable quarterly results and FDA drug approvals should help lift these five names.

Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Reports Third Quarter 2017 Financial Results And Business Update

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for...

4 Small-Caps on My Earnings Watch List

4 Small-Caps on My Earnings Watch List

We are coming my favorite part of earnings season -- when these small-caps report.

Synergy Pharmaceuticals To Report Third Quarter 2017 Financial Results And Host Conference Call And Webcast

Synergy Pharmaceuticals To Report Third Quarter 2017 Financial Results And Host Conference Call And Webcast

Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced it intends to release third quarter 2017 financial results after the NASDAQ market close on Thursday, November 9, 2017.